BIOMAT Database Logo BIOMAT Database Logo

p53-induced apoptosis in the human T-ALL cell line CCRF-CEM. 1997

S Geley, and B L Hartmann, and R Hattmannstorfer, and M Löffler, and M J Ausserlechner, and D Bernhard, and R Sgonc, and E M Strasser-Wozak, and M Ebner, and B Auer, and R Kofler
Institute for General and Experimental Pathology, Division of Molecular Pathophysiology, University of Innsbruck, Austria.

The tumor suppressor p53 has been implicated in apoptosis induction and is mutated in human T-ALL CCRF-CEM cells. To investigate possible consequences of wild-type p53 loss, we reconstituted CEM-C7H2, a subclone of CCRF-CEM, with a temperature-sensitive p53 allele (p53ts). Stably transfected lines expressed high levels of p53ts and shift to the permissive temperature (32 degrees C) caused rapid induction of p53-regulated genes, such as p21(CIP1/WAF1), mdm-2 and bax. This was followed by extensive apoptosis within 24 h to 36 h, supporting the notion that mutational p53 inactivation contributed to the malignant phenotype. p53-dependent apoptosis was preceded by digestion of poly(ADP-ribose) polymerase, a typical target of interleukin-1beta-converting enzyme (ICE)-like proteases/caspases, and was markedly resistant to the ICE/caspase-1 and FLICE/caspase-8 inhibitor acetyl-Tyr-Val-Ala-Asp.chloromethylketone (YVAD), but sensitive to the CPP32/caspase-3 inhibitor benzyloxycarbonyl-Asp-Glu-Val-Asp.fluoromethylketone (DEVD) and benzyloxycarbonyl-Val-Ala-Asp.fluoromethylketone (zVAD), a caspase inhibitor with broader specificity. This indicated an essential involvement of caspases, but argued against a significant role of ICE/caspase-1 or FLICE/caspase-8. Actinomycin D or cycloheximide prevented cell death, suggesting that, in this system, p53-induced apoptosis depends upon macromolecule biosynthesis. Introduction of functional p53 into CEM cells enhanced their sensitivity to the DNA-damaging agent doxorubicin, but not to the tubulin-active compound vincristine. Thus, mutational p53 inactivation in ALL might entail relative resistance to DNA-damaging, but not to tubulin-destabilizing, chemotherapy.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011065 Poly(ADP-ribose) Polymerases Enzymes that catalyze the transfer of multiple ADP-RIBOSE groups from nicotinamide-adenine dinucleotide (NAD) onto protein targets, thus building up a linear or branched homopolymer of repeating ADP-ribose units i.e., POLY ADENOSINE DIPHOSPHATE RIBOSE. ADP-Ribosyltransferase (Polymerizing),Poly ADP Ribose Polymerase,Poly(ADP-Ribose) Synthase,Poly(ADP-ribose) Polymerase,PARP Polymerase,Poly ADP Ribose Transferase,Poly ADP-Ribose Synthase,Poly(ADP-Ribose) Transferase,Poly(ADPR) Polymerase,Poly(ADPribose) Polymerase,Poly ADP Ribose Synthase,Polymerase, PARP,Synthase, Poly ADP-Ribose
D011500 Protein Synthesis Inhibitors Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. Protein Synthesis Antagonist,Protein Synthesis Antagonists,Protein Synthesis Inhibitor,Antagonist, Protein Synthesis,Antagonists, Protein Synthesis,Inhibitor, Protein Synthesis,Inhibitors, Protein Synthesis,Synthesis Antagonist, Protein,Synthesis Inhibitor, Protein
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D003513 Cycloheximide Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis. Actidione,Cicloheximide
D003546 Cysteine Endopeptidases ENDOPEPTIDASES which have a cysteine involved in the catalytic process. This group of enzymes is inactivated by CYSTEINE PROTEINASE INHIBITORS such as CYSTATINS and SULFHYDRYL REAGENTS.
D003609 Dactinomycin A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Actinomycin,Actinomycin D,Meractinomycin,Cosmegen,Cosmegen Lyovac,Lyovac-Cosmegen,Lyovac Cosmegen,Lyovac, Cosmegen,LyovacCosmegen
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme

Related Publications

S Geley, and B L Hartmann, and R Hattmannstorfer, and M Löffler, and M J Ausserlechner, and D Bernhard, and R Sgonc, and E M Strasser-Wozak, and M Ebner, and B Auer, and R Kofler
The Protein Profile of the Human Immature T-cell Line CCRF-CEM.
January 2005, Cancer genomics & proteomics,
S Geley, and B L Hartmann, and R Hattmannstorfer, and M Löffler, and M J Ausserlechner, and D Bernhard, and R Sgonc, and E M Strasser-Wozak, and M Ebner, and B Auer, and R Kofler
Investigation of BAX and BCL2 expression and apoptosis in a resveratrol- and prednisolone-treated human T-ALL cell line, CCRF-CEM.
March 2018, Blood research,
S Geley, and B L Hartmann, and R Hattmannstorfer, and M Löffler, and M J Ausserlechner, and D Bernhard, and R Sgonc, and E M Strasser-Wozak, and M Ebner, and B Auer, and R Kofler
Mechanisms of the apoptotic activity of Cl-F-araA in a human T-ALL cell line, CCRF-CEM.
September 2002, Cancer chemotherapy and pharmacology,
S Geley, and B L Hartmann, and R Hattmannstorfer, and M Löffler, and M J Ausserlechner, and D Bernhard, and R Sgonc, and E M Strasser-Wozak, and M Ebner, and B Auer, and R Kofler
Growth and differentiation of a human T-cell leukemia cell line, CCRF-CEM, grafted in mice.
December 1989, Cancer research,
S Geley, and B L Hartmann, and R Hattmannstorfer, and M Löffler, and M J Ausserlechner, and D Bernhard, and R Sgonc, and E M Strasser-Wozak, and M Ebner, and B Auer, and R Kofler
Cell cycle regulation of membrane glucocorticoid receptor in CCRF-CEM human ALL cells: correlation to apoptosis.
September 1997, The American journal of physiology,
S Geley, and B L Hartmann, and R Hattmannstorfer, and M Löffler, and M J Ausserlechner, and D Bernhard, and R Sgonc, and E M Strasser-Wozak, and M Ebner, and B Auer, and R Kofler
Cytotoxicity of arctigenin and matairesinol against the T-cell lymphoma cell line CCRF-CEM.
September 2015, The Journal of pharmacy and pharmacology,
S Geley, and B L Hartmann, and R Hattmannstorfer, and M Löffler, and M J Ausserlechner, and D Bernhard, and R Sgonc, and E M Strasser-Wozak, and M Ebner, and B Auer, and R Kofler
Identification of external membrane proteins of the T lymphoblast cell line CCRF-CEM.
October 1979, Experimental cell research,
S Geley, and B L Hartmann, and R Hattmannstorfer, and M Löffler, and M J Ausserlechner, and D Bernhard, and R Sgonc, and E M Strasser-Wozak, and M Ebner, and B Auer, and R Kofler
Deoxyadenosine toxicity in an adenosine deaminase-inhibited human CCRF-CEM T-lymphoblastoid cell line causes cell swelling.
December 1992, Biochimica et biophysica acta,
S Geley, and B L Hartmann, and R Hattmannstorfer, and M Löffler, and M J Ausserlechner, and D Bernhard, and R Sgonc, and E M Strasser-Wozak, and M Ebner, and B Auer, and R Kofler
Multiple mechanisms of adriamycin resistance in the human leukemia cell line CCRF-CEM.
February 1989, Biochemical pharmacology,
S Geley, and B L Hartmann, and R Hattmannstorfer, and M Löffler, and M J Ausserlechner, and D Bernhard, and R Sgonc, and E M Strasser-Wozak, and M Ebner, and B Auer, and R Kofler
Human T-cell hybrids secreting lymphokines: effect of different parent cell clones of the human T-cell acute lymphoblastoid leukaemia line CCRF-CEM.
May 1986, Scandinavian journal of immunology,
Copied contents to your clipboard!